

1199SEIU Benefit and Pension Funds

SPECIALTY MEDICATIONS

available through Accredo Health Group, Inc., an Express Scripts specialty pharmacy

Call toll-free **(800) 803-2523**, 8:00 am to 8:00 pm, eastern time, Monday through Friday, to confirm that your medication is covered.

Effective as of July 1, 2018

- ◆ *Abraxane*® (paclitaxel protein-bound particles) [PA]
Actemra™ (tocilizumab) [PA] [QD]
Actemra™ SQ (tocilizumab) [PA] [QD] [PICA]
- ◆ *Actimmune*® (interferon gamma-1b) [PA] [PICA]
- ◆ *Adcetris*® (brentuximab vedotin) [PA]
Adcirca® (tadalafil) [PA] [ST] [QD]
Adempas® (riociguat) [PA]
Advate® (antihemophilic factor [recombinant]) [CPA]
Adynovate™ (antihemophilic Factor VIII [recombinant]) [CPA]
- ◆ *Afinitor*® (everolimus) [PA] [QD] [PICA]
Afstyla® (antihemophilic Factor [recombinant]) [CPA]
- ◆ *Alcensa*® (alectinib) [PA] [PICA] [QD] [SF]
Aldurazyme® (laronidase) [CPA]
Alphanate® (antihemophilic factor [human]) [CPA]
AlphaNine® SD (coagulation factor IX [human]) [CPA]
Alprolix™ (coagulation factor IX [recombinant]) [CPA]
- ◆ *Alunbrig*™ (brigatinib) [PA] [PICA]
Ampyra™ (dalfampridine) [PA] [QD]
Apokyn® (apomorphine hydrochloride) [QD]
Aralast® NP (alpha[1]-proteinase inhibitor [human]) [PA]
- ◆ *Aranesp*® (darbeoetin alfa) [PA] [PICA]
Arcalyst® (rilonacept) [PA] [QD] [PICA]
- * *Arixtra*® (fondaparinux sodium) [PICA]
- ◆ *Arranon*® (nelarabine) [PA]
- ◆ *Arzerra*® (ofatumumab) [PA]
Aubagio® (teriflunomide) [PA]
- ◆ *Avastin*® (bevacizumab) [PA] [QD]
Avonex® (interferon beta-1a) [PA] [PICA]
Azacitidine (GENERIC) [PA] [QD]
Bebulin® VH (factor IX complex) [CPA]
- ◆ *Bendeka*™ (bendamustine) [PA]
BeneFIX® (coagulation factor IX [recombinant]) [CPA]
Benlysta® (belimumab) [PA]
Berinert® (c1 esterase inhibitor [human]) [PA] [QD]
Betaseron® (interferon beta-1b) [PA] [PICA]
Bethkis® (tobramycin)
Bexarotene (GENERIC)
Bivigam™ (immune globulin intravenous [human]) [PA]
- ◆ *Bosulif*® (bosutinib) [PA] [SF] [QD]
Botox® (botulinum toxin type A) [PA] [PICA]
- ◆ *Capecitabine* (GENERIC) [PICA]
Carbaglu™ (carglumic acid)
Carimune® NF (immune globulin intravenous [human]) [PA]
Cayston® (aztreonam) [PA] [QD]
Cerdelga® (eliglustat tartrate)
Cerezyme® (imiglucerase) [CPA]
Cimzia® (certolizumab pegol) [ST] [PA] [QD] [PICA]
Cinryze® (c1 esterase inhibitor) [PA] [QD]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.
[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners.
Subject to change.

- ◆ *Cabometyx*TM (cobozantinib) [PA][QD] [SF]
- Copaxone*[®] (glatiramer acetate) [PA] [PICA]
- Copegus*[®] (ribavirin) [PA] [SF]
- Corifact*[®] (factor XIII [human]) [CPA]
- Cosentyx*[®] (secukinumab) [PA] [PICA]
- ◆ *Cotellic*[®] (cobimetinib) [PA] [PICA] [QD]
- Cuvitru*TM (immune globulin 20% [human])
- ◆ *Cyramza*[®] (ramucirumab) [PICA]
- CytoGam*[®] (cytomegalovirus immune globulin intravenous [human]) [CPA]
- Cytovene*[®] IV (ganciclovir sodium)
- Daklinza*TM (daclatasvir) [PA] [QD] [SF]
- ◆ *Darzalex*[®] (daratumumab) [PA]
- ◆ *Decitabine* (GENERIC)
- Duopa*[®] (levodopa/carbidopa)
- Dupixent*[®] (dupilumab) [PA] [QD]
- Durolane*[®] (hyaluronic acid) [PA]
- Dysport*[®] (abobotulinumtoxinA) [PA]
- Egrifta*[®] (tesamorelin) [PICA]
- Elaprase*[®] (idursulfase) [CPA]
- Ellelyso*TM (taliglucerase alfa)
- ◆ *Eligard*[®] (leuprolide acetate) [PA][PICA]
- Eloctate*TM (antihemophilic factor [recombinant]) [CPA]
- ◆ *Empliciti*TM(elotuzumab) [PA]
- Enbre*[®] (etanercept) [PA] [QD] [PICA][ST]
- * *Enoxaparin* sodium (GENERIC) [PICA]
- Entyvio*[®] (vedolizumab) [PA]
- Epclusa*[®] (sofosbuvir/velpatasvir) [PA][QD][SF]
- ◆ *Epogen*[®] (epoetin alfa) [PA] [PICA]
- Epoprostenol* sodium (GENERIC)
- ◆ *Erbix*[®] (cetuximab) [PA] [QD]
- ◆ *Erivedge*TM (vismodegib) [PA] [QD] [SF]
- ◆ *Erleada*TM (apalutamide) [PICA] [PA]
- Esbriet*[®] (pirfenidone) [PA]
- Euflexxa*[®] (sodium hyaluronate) [PA] [QD]
- Exjade*[®] (deferasirox) [SF] [PA]
- Extavia*[®] (interferon beta-1b) [PA] [PICA]
- Eylea*TM (aflibercept) [PA]
- Fabrazyme*[®] (agalsidase beta) [CPA]
- ◆ *Farydak* (panobinostat) [PA] [PICA] [QD]
- Fasenra*TM (benralizumab) [PA]
- Feiba*[®] VH (anti-inhibitor coagulant complex) [CPA]
- Firazyr*[®] (icatibant) [PA] [QD] [PICA]
- ◆ *Firmagon*[®] (degarelix) [PA] [PICA]
- Flebogamma*[®] (immune globulin [human]) [PA]
- Flolan*[®] (epoprostenol sodium) [PA]
- ◆ *Foloty*TM (pralatrexate) [PA]
- * *Fondaparinux* sodium (GENERIC) [PICA]
- Forteo*[®] (teriparatide [rDNA origin]) [PA] [PICA]
- * *Fragmin*[®] (dalteparin sodium) [PICA]
- GamaSTAN*[®] S/D (immune globulin [human])
- Gammagard*[®] Liquid (immune globulin [human]) [PA]
- Gammagard*[®] S/D (immune globulin [human]) [PA]
- Gammaked*TM (immune globulin, gamma caprylate [IGG]) [PA]
- Gammaplex*[®] (immune globulin [human]) [PA]
- Gamunex*[®] (immune globulin [human]) [PA]
- Ganciclovir* (GENERIC)
- Gattex*[®] (teduglutide)
- ◆ *Gazyva*TM (obinutuzumab) [PA]
- Gel-One*[®] (hyaluronate sodium) [PA]
- Gelsyn-3*TM (hyaluronate sodium) [PA]
- Genotropin*[®] (somatotropin [rDNA origin]) [PA] [PICA]
- Gilenya*TM (afatinib) [PA]
- ◆ *Gilotrif*TM (afatinib) [PA] [PICA] [QD]
- Glassia*TM (alpha [1]-proteinase inhibitor [human]) [PA] [ST]
- Glatiramer* (GENERIC) [PA] [PICA]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery. [PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- Glatopa*® (glatiramer acetate) [PA] [PICA]
- ◆ *Granix*™ (tbo-filgrastim) [PA] [PICA]
 - Haegarda*® (c1 esterase inhibitor) [PA] [PICA]
 - ◆ *Halaven*™ (eribulin mesylate) [PA]
 - Harvon*™ (ledipasvir/sofosbuvir) [PA] [QD] [SF]
 - Helixate*® FS (antihemophilic factor [recombinant]) [CPA]
 - Hemlibra*® (emicizumab) [PICA]
 - Hemofil*® M (antihemophilic factor [human]) [CPA]
 - ◆ *Herceptin*® (trastuzumab) [PA]
 - Hetlioz*™ (tasimelteon) [PA]
 - Hizentra*™ (immune globulin subcutaneous [human]) [PA]
 - H.P. Acthar*® Gel (corticotropin) [PA] [QD]
 - Humate-P*® (antihemophilic factor/von Willebrand factor complex [human]) [CPA]
 - Humatrope*® (somatropin [rDNA origin]) [PA] [PICA]
 - Humira*® (adalimumab) [PA] [QD] [PICA]
 - Hyalgan*® (sodium hyaluronate) [PA] [QD]
 - ◆ *Hycamtin*® capsules (topotecan) [PA]
 - Hymovis*® (hyaluronate sodium) [PA]
 - HyperRho*® S/D (Rho[D] immune globulin [human])
 - Hyqvia*™ (immune globulin infusion 10% [human] with recombinant) [PA]
 - Ibandronate Sodium* (GENERIC) [PA]
 - ◆ *Ibrance*® (palbociclib) [PA] [PICA] [QD]
 - Idelvion*® (coagulation factor IX [recombinant]) [CPA]
 - ◆ *Idhifa*® (enasidenib) [PICA]
 - Ilaris*® (canakinumab) [PA] [QD]
 - Iluvien*® (Fluocinolone)
 - ◆ *Imatinib* (GENERIC) [PA] [PICA] [QD]
 - ◆ *Imfinzi*™ (durvalumab) [PA]
 - Increlex*® (mecasermin [rDNA origin]) [PA] [PICA]
 - Inflectra*™ (infliximab-dyyb) [PA]
 - ◆ *Inlyta*® (axitinib) [PA] [QD] [PICA] [SF]
 - ◆ *Intron*® A (interferon alfa-2b) [PA][PICA]
 - * *Iprivask*® (desirudin)
 - ◆ *Iressa*® [PA] [PICA] [QD] [SF]
 - ◆ *Istodax*® (romidepsin) [PA] [QD]
 - ◆ *Ixempra*® (ixabepilone) [PA]
 - Ixinity*® (coagulation factor IX [recombinant]) [CPA]
 - Jadenu*™ (deferasirox) [SF] [PA]
 - ◆ *Jakafi*™ (ruxolitinib) [PA] [SF] [QD]
 - ◆ *Jevtana*® (cabazitaxel) [PA] [QD]
 - Juxtapid*® (lomitapide)
 - ◆ *Kadcyla*™ (ado-trastuzumab emtansine) [PA]
 - Kalbitor*® (ecallantide) [PA] [QD]
 - Kalydeco*™ (ivacaftor) [PA] [SF]
 - Kanuma*™ (sebelipase alfa)
 - Kevzara*® (sarilumab) [QD] [PA] [PICA]
 - ◆ *Kisqali*® (ribociclib) [PA] [QD] [PICA]
 - Kitabis Pak*® (Tobramycin)
 - Koate*®-DVI (antihemophilic factor [human]) [CPA]
 - Kogenate*® FS (antihemophilic factor [recombinant]) [CPA]
 - Kovaltry*® (antihemophilic factor VIII) [CPA]
 - Krystexxa*™ (pegloticase) [PA]
 - Kuvan*® (sapropterin dihydrochloride) [PA]
 - Kynamro*™ (mipomersen sodium)
 - ◆ *Lartruvo*™ (olaratumab) [PA]
 - Lemtrada*™ (alemtuzumab) [PA]
 - ◆ *Lenvima*™ (lenvatinib) [PA] [PICA] [SF]
 - Letairis*® (ambrisentan) [PA] [QD]
 - ◆ *Leukine*® (sargramostim) [PA] [PICA]
 - Leuprolide acetate* (GENERIC) [PICA]
 - Liletta*™ (levonorgestrel-releasing intrauterine device)
 - ◆ *Lonsurf*® (tipiracil/trifluridine) [PA] [PICA]
 - * *Lovenox*® (enoxaparin sodium) [PICA]
 - Lucentis*® (ranibizumab) [PA]
 - Lumizyme*™ (alglucosidase alfa) [CPA]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery. [PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- Lupaneta*[™] (leuprolide acetate) [PICA]
Lupron Depot[®] (leuprolide acetate) [PA] [PICA]
Lupron Depot-PED[®] (leuprolide acetate) [PA] [PICA]
- ◆ *Lutathera*[®] (lutetium Lu 177 dotatate) [PA]
Luxturna[™] (voretigene) [CPA]
- ◆ *Lynparza*[™] (olaparib) [PA][SF][PICA]
Macugen[®] (pegaptanib sodium injection) [PA]
Makena[™] (hydroxyprogesterone caproate) [PA]
Mavyret[™] (glecaprevir/pibrentasvir) [QD] [SF] [PA]
- ◆ *Mekinist*[™] (trametinib) [PA] [PICA] [QD]
Mepsevii[™] (vestronidase alfa)
MICRhoGAM[®] (Rho[D] immune globulin [human])
Mitoxantrone HCl (GENERIC)
Moderiba[™] (ribavirin) [PA]
Monoclate-P[®] (antihemophilic factor [human]) [CPA]
Mononine[®] (coagulation factor IX [human]) [CPA]
Monovisc[®] (hyaluronate sodium) [PA] [QD]
- ◆ *Mozobil*[®] (plerixafor) [QD] [PA] [PICA]
Myalept[™] (metreleptin) [PA] [PICA]
Myobloc[®] (botulinum toxin type B) [PA] [PICA]
Naglazyme[®] (galsulfase) [CPA]
Natpara[®] (parathyroid hormone) [PA] [PICA]
- ◆ *Nerlynx*[™] (neratinib) [PICA]
- ◆ *Neulasta*[®] (pegfilgrastim) [PA] [PICA]
Neumega[®] (oprelvekin) [PICA]
- ◆ *Neupogen*[®] (filgrastim) [PA] [PICA]
- ◆ *Nexavar*[®] (sorafenib) [PA] [QD] [PICA] [SF]
- ◆ *Ninlaro*[®] (ixazomib) [PA] [PICA] [QD]
Norditropin[®] (somatropin [rDNA origin]) [PA] [PICA]
Norditropin/Nordiflex[®] (somatropin [rDNA origin]) [PA] [PICA]
Northera[®] (droxidopa) [PA]
NovoEight[®] (antihemophilic factor VIII [recombinant]) [CPA]
NovoSeven[®] RT (coagulation factor VIIa [recombinant]) [CPA]
- Nplate*[®] (romiplostim) [PA]
Nucala[™] (mepolizumab) [PA]
Nuplazid[™] [SF]
Nutropin[®] (somatropin [rDNA origin]) [PA] [PICA]
Nutropin AQ[®] (somatropin [rDNA origin]) [PA] [PICA]
Nuwig[®] (antihemophilic Factor VIII [recombinant]) [CPA]
Ocaliva[™] (obeticholic acid) [PA][QD]
Ocrevus[™] (ocrelizumab) [PA]
Octagam[®] (immune globulin intravenous [human]) [PA]
Octreotide acetate (GENERIC)
- ◆ *Odomzo*[®] (sonidegib) [PA][PICA]
Ofev[®] (Nintedanib) [PA]
Olysio[™] (simeprevir) [PA] [SF]
Omnitrope[®] (somatropin) [PA] [PICA]
- ◆ *Opdivo*[®] (Nivolumab) [PA]
Opsumit[®] (macitentan) [PA]
Orencia[®] IV (abatacept intravenous) [PA] [PICA]
Orencia[®] SC (abatacept subcutaneous) [ST] [PA] [QD] [PICA]
Orenitram[™] (treprostinil) [PA]
Orkambi[®] (lumacaftor/ivacaftor) [PA]
OrthoVisc[®] (hyaluronate sodium) [PA]
Otezla[®] (apremilast) [PA] [ST]
Ozurdex[™] (dexamethasone)
- ◆ *Pegasys*[®] (peginterferon alfa-2a) [PA] [PICA] [SF]
- ◆ *Perjeta*[™] (pertuzumab) [PA]
Plegidy[™] (peginterferon Beta-1A) [PA] [PICA]
- ◆ *Pomalyst*[®] (pomalidomide) [PA] [PICA]
- ◆ *Portrazza*[®] (necitumumab) [PICA]
Praluent[®] (alirocumab) [PA]
Privigen[®] (immune globulin intravenous [human]) [PA]
- ◆ *Procrit*[®] (epoetin alfa) [PA] [PICA]
Procysbi[™] (cysteamine bitartrate)
Profilnine[®] SD (factor IX complex [human]) [CPA]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery. [PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- ◆ *Proleukin*® (aldesleukin) [PA]
- Prolia*™ (denosumab) [PA] [QD]
- Promacta*® (eltrombopag) [PA] [QD]
- ProThelia*™ (sucralfate)
- Pulmozyme*® (dornase alfa)
- Ravicti*™ (glycerol phenylbuterate)
- Rebetol*® (ribavirin) [PA]
- Rebif*® (interferon beta-1a) [PA] [PICA]
- Rebinyr*® (coagulation factor IX [recombinant]) [CPA]
- Recombinate*™ (antihemophilic factor [recombinant]) [CPA]
- Remicade*® (infliximab) [PA]
- Remodulin*® (treprostinil sodium)
- Renflexis*™ (infliximab) [PA]
- Repatha*™ (evolocumab) [PA]
- Retisert*® (fluocinolone acetonide) [QD]
- Revatio*® injection (sildenafil citrate) [PA] [QD]
- Revatio*® tablets (sildenafil citrate) [PA] [QD]
- ◆ *Revlimid*® (lenalidomide) [PA] [QD] [PICA]
- RhoGAM*® (RHo[D] immune globulin [human])
- Rhophylac*® (RHo[D] immune globulin intravenous [human])
- RiaSTAP*® (fibrinogen)
- RibaPak*® (GENERIC) [PA]
- Ribasphere*® (GENERIC) [PA] [SF]
- Ribavirin* (GENERIC) [PA] [SF]
- ◆ *Rituxan*® (rituximab) [PA]
- Rixubis*™ (coagulation factor IX [recombinant]) [CPA]
- Ruconest*™ (c1 Esterase Inhibitor [recombinant]) [PA]
- ◆ *Rydapt*® (midostaurin) [PA]
- Sabri*® (vigabatrin)
- Saizen*® (somatropin [rDNA origin]) [PA] [PICA]
- Samsca*® (tolvaptan) [QD]
- Sandostatin*® (octreotide acetate) [PICA]
- Sandostatin LAR*® (octreotide/IM) [PICA]
- Serostim*® (somatropin [rDNA origin]) [PA] [PICA]
- Signifor*® (pasireotide dispartate) [PA]
- Signifor*® LAR (pasireotide pamoate) [PA] [PICA]
- Sildenafil* (GENERIC) [QD]
- Siliq* (brodalumab)™ [QD] [PA] [PICA]
- Simponi*™ (golimumab) [ST] [PA] [QD] [PICA]
- Simponi*™ ARIA™ (golimumab) [ST] [PA] [QD] [PICA]
- Soliris*® (eculizumab)
- Somatuline Depot*® (lanreotide) [PICA]
- Somavert*® (pegvisomant)
- Sovaldi*™ (sofosbuvir) [PA] [QD] [SF]
- Spinraza*™ (nusinersen) [PA]
- ◆ *Sprycel*® (dasatinib) [PA] [QD] [PICA] [SF]
- Stelara*™ (ustekinumab) [PA] [QD] [PICA]
- Stimate*® (desmopressin acetate)
- ◆ *Stivarga*® (regorafenib) [PA] [QD]
- Sublocade*™ (buprenorphine) [PA]
- Supartz*® (sodium hyaluronate) [PA] [QD]
- Supprelin*® LA (histrelin acetate)
- ◆ *Sutent*® capsules (sunitinib malate) [PICA] [QD]
- Sylatron*™ (peginterferon alfa-2b)
- Sylvant*™ (siltuximab)
- Symdeko*™ (tezacaftor/ivacaftor) [PA]
- Synagis*® (palivizumab) [PA] [QD]
- Synvisc*®/ *Synvisc-ONE*® (hylan G-F 20) [PA] [QD]
- ◆ *Tafinlar*® (dabrafenib) [PA] [PICA] [QD] [SF]
- ◆ *Tagrisso*™ (osimertinib) [PA] [PICA] [QD]
- Taltz*® (ixekizumab) [PA] [QD] [PICA] [ST]
- ◆ *Tarceva*® (erlotinib) [PA] [QD] [PICA] [SF]
- ◆ *Tasigna*® (nilotinib) [PA] [QD] [PICA] [SF]
- ◆ *Tecentriq*™ (atezolizumab) [PA]
- Tecfidera*™ (dimethyl fumarate) [PA]
- Technivie*™ (ombitasvir/paritaprevir/ritonavir) [PA] [SF]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery. [PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- ◆ *Temodar*® (temozolomide) [PA] [PICA]
Temozolomide (GENERIC) [PICA]
Tetrabenazine (GENERIC)
- ◆ *Thalomid*® (thalidomide) [PA] [PICA]
Tobi® (tobramycin)
Tobi-Podhaler® (tobramycin)
Tobramycin (GENERIC)
- ◆ *Torisel*® (temsirolimus) [PA]
Tracleer® (bosentan) [PA] [QD]
- ◆ *Treanda*® (bendamustine) [PA]
Tremfya™ (guselkumab) [PA] [ST] [PICA]
Tretten® (coagulation factor XIII A-subunit [recombinant]) [CPA]
- ◆ *Tykerb*® (lapatinib) [PA] [QD] [PICA]
Tymlos™ (abaloparatide) [PA] [PICA]
Tysabri® (natalizumab) [PA] [QD]
Tyvaso® (treprostinil) [PA]
Uptravi® (selexipag)
- ◆ *Valchlor*™ (mechlorethamine) [PA]
- ◆ *Vantas*® (histrelin) [PA]
- ◆ *Vectibix*® (panitumumab) [PA]
- ◆ *Velcade*® (bortezomib) [PA]
Veletri® (epoprostenol sodium)
Veltassa™ (paitromer)
Ventavis® (iloprost) [PA] [QD]
- ◆ *Verzenio*™ (abemaciclib) [PICA] [SF]
- ◆ *Vidaza*® (azacitidine) [PA] [QD] [PICA]
Viekira Pak (ombitasvir/paritaprevir/ritonavir co-packed with dasabuvir) [PA] [QD] [SF]
Vigabatrin (GENERIC)
Vimizim™ (elosulfase alfa) [CPA]
Visco-3™ (sodium hyaluronate) [PA]
Visudyne® (verteporfin)
Vivitrol® (naltrexone)
- Vosevi*® (sofosbuvir/velpatasvir/voxilaprevir) [QD] [SF] [PA]
- ◆ *Votrient*® (pazopanib) [PA] [QD] [PICA] [SF]
Vpriv™ (velaglucerase alfa) [CPA]
Wilate® (von Willebrand factor/coagulation factor VIII complex [human]) [CPA]
WinRho SDF® (Rho[D] immune globulin intravenous [human])
- ◆ *Xalkori*® (crizotinib) [PA] [QD] [PICA] [SF]
Xeljanz® (tofacitinib citrate) [PA]
Xeljanz XR® (tofacitinib) [PA]
Xenazine® (tetrabenazine) [PA] [QD] [SF]
Xeomin® (incobotulinumtoxinA) [PA]
- ◆ *Xgeva*™ (denosumab) [QD]
Xolair® (omalizumab) [PA] [QD]
- ◆ *Xtandi*® (enzalutamide) [PA] [QD] [SF]
Xyntha® (antihemophilic factor [recombinant]) [CPA]
- ◆ *Yervoy*™ (ipilimumab) [PA] [QD]
- ◆ *Zaltrap*® (afibercept) [PA]
- ◆ *Zarxio* (GENERIC) [PA] [PICA]
Zavesca® (miglustat) [QD][CPA]
- ◆ *Zelboraf*™ (vemurafenib) [PA] [QD] [PICA] [SF]
Zemaira® (alpha [1]-proteinase inhibitor [human]) [PA]
Zepatier™ (elbasvir/grazoprevir) [PA] [QD] [SF]
- ◆ *Zoladex*® (goserelin acetate) [PA] [PICA]
- ◆ *Zolinza*® (vorinostat) [PA] [QD] [PICA] [SF]
Zomacton® (somatropin [rDNA origin]) [PA] [PICA]
Zorbitive® (somatropin [rDNA origin]) [PA] [PICA]
- ◆ *Zykadia*™ (ceritinib) [PA] [PICA] [QD] [SF]
- ◆ *Zytiga*™ (abiraterone acetate) [PA] [QD] [PICA] [SF]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact **(888) 910-1199** for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

* This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery. [PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.